Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1

Interventions

Rituximab 6Lenalidomide 3Bendamustine Hydrochloride 3pirtobrutinib 2Cyclophosphamide 2venetoclax 1umbralisib 1ublituximab 1tocilizumab 1obinutuzumab 1idelalisib 1glofitamab 1fludarabine 1atezolizumab 1acalabrutinib 1Vincristine 1Standard of Care 1Prednisone 1Doxorubicin 1Brentuximab Vedotin 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Lymphoma, Non-Hodgkin × fludarabine × Clear all
NCT04245839 2025-11-05

TRANSCEND FL

Celgene

Phase 2 Active not recruiting
276 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡